Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
Provided By GlobeNewswire
Last update: Mar 14, 2025
- Company’s patented desmopressin oral solution successfully passed pivotal bioequivalence study -
- Company expects to submit New Drug Application (NDA) in April 2025 -
